Cognition Therapeutics (CGTX) Amortization of Deferred Charges (2020 - 2021)
Cognition Therapeutics (CGTX) reported Amortization of Deferred Charges of $9000.0 for Q2 2021, down 59.09% on a QoQ basis from $22000.0 in Q1 2021.
Cognition Therapeutics (CGTX) has 2 years of Amortization of Deferred Charges data on file, last reported at $9000.0 in Q2 2021.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $9000.0 in Q2 2021, while the trailing twelve-month figure through Dec 2021 was $31000.0 (changed N/A YoY) and the FY2021 annual result came in at $31000.0, down 42.59% from the prior year.
- Amortization of Deferred Charges fell to $9000.0 in Q2 2021 per CGTX's latest filing, from $22000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $22000.0 in Q1 2021 and bottomed at $9000.0 in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 20,000.00 |
| Dec 31, 2020 | 20,000.00 |
| Sep 30, 2020 | 18,000.00 |
| Sep 30, 2020 | 18,000.00 |